Special Issue "Multitarget Drug Discovery and Pharmacology"
Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 60954
Interests: medicinal chemistry; organic synthesis; enzyme inhibitors; antiproliferative agents; anti-Alzheimer's agents; polyphenols; iminosugars; coumarins; steroids; antioxidants; organoselenium compounds
Special Issues, Collections and Topics in MDPI journals
The incidence of chronic multifactorial diseases has been increasing dramatically in the last few years, which has led to an important economic burden to both families and public health systems. Apart from a high prevalence within our society, diseases like diabetes, cancer, and cardiovascular or neurodegenerative diseases, among others, also share a tremendous complex etiology. A plethora of different factors can develop such diseases, such as genetic, environmental or lifestyles, yielding a complicated pathological network many of whose components are not even completely understood nowadays.
For this reason, the classical one drug–one target approach, where drugs are designed for interacting only with a single biological target, avoiding interactions with off-target receptors, is not effective against multifactorial diseases. The use of drug cocktails is usually the best available option for the treatment of complex diseases, but it is endowed with numerous disadvantages, such as undesired drug–drug interactions leading to severe side-effects, or reduced patient compliance for the intake of several drugs.
The lack of efficiency of traditional drug therapies has stimulated pharmacological research for searching alternative approaches; as a result, the multi-target-directed ligands approach (MTDL) recently emerged with the aim of overcoming these limitations; in this approach, small molecules are capable of simultaneously modulating several relevant therapeutic targets of a certain disease. Interest in MTDLs is experiencing a continuous increase, supported by the number of scientific publications on this topic, together with the fact that numerous drugs with a multitarget mode of action have already been approved by FDA.
The aim of this Special Issue is to provide an overview of recent pharmacological research of MTDL’s against multifactorial diseases; topics will include but are not limited to cancer, Alzheimer’s, Parkinson, diabetes, and infectious diseases.
Prof. Dr. Óscar López
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Multifactorial diseases
- Multitarget drugs
- Neurodegenerative diseases
- Infectious diseases